**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 60839

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients**

Huang YC *et al.* Clinicopathological features and prognostic factors of GEP-MiNEN

Yu-Chen Huang, Ning-Ning Yang, Hong-Chun Chen, Yuan-Li Huang, Wen-Tian Yan, Ru-Xue Yang, Nan Li, Shan Zhang, Pan-Pan Yang, Zhen-Zhong Feng

**Yu-Chen Huang, Ning-Ning Yang, Hong-Chun Chen, Yuan-Li Huang, Wen-Tian Yan, Nan Li, Zhen-Zhong Feng,** Department of Pathology, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province, China

**Yu-Chen Huang, Ning-Ning Yang, Hong-Chun Chen, Yuan-Li Huang, Wen-Tian Yan, Nan Li, Zhen-Zhong Feng,** Department of Pathology, Bengbu Medical College, Bengbu 233000, Anhui Province, China

**Ru-Xue Yang,** Department of Pathology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China

**Shan Zhang,** Department of Pathology, Second People's Hospital of Hefei, Hefei 230000, Anhui Province, China

**Pan-Pan Yang,** Department of Pathology, Second Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China

**Author contributions:** Huang YC collected the clinical data and prepared the manuscript; Huang YC and Yang NN designed the study and supervised the statistical data; Huang YC and Chen HC designed the research and contributed to the analyses; Huang YL, Yan WT, Yang RX, Li N, Zhang S, and Yang PP provided clinical advice; Feng ZZ made the pathologic diagnosis and supervised the report.

**Supported by**theNatural Science Foundation of Anhui Province, No. 1908085MH275; the Key Project of Science and Technology Development Foundation of Bengbu Medical College, No. BYKF201710; and the Graduate Innovation Program of Bengbu Medical College, No. Byycx20064.

**Corresponding author: Zhen-Zhong Feng, PhD, Professor,** Department of Pathology, First Affiliated Hospital of Bengbu Medical College, No. 287 Changhuai Road, Longzihu District, Bengbu 233000, Anhui Province, China. fzz18297301626@163.com

**Received:** November 15, 2020

**Revised:** December 24, 2020

**Accepted:** January 13, 2021

**Published online:**

**Abstract**

BACKGROUND

The incidence of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) is low. To improve our understanding of this rare tumor type and optimally guide clinical treatment, associated risk factors, clinical manifestations, and prognosis must be explored.

AIM

To identify risk factors that influence the prognosis of patients with gastroenteropancreatic MiNEN (GEP-MiNEN).

METHODS

We retrospectively analyzed the clinical data of 46 patients who were diagnosed with GEP-MiNEN at the First Affiliated Hospital of Bengbu Medical College (Anhui, China) between January 2013 and December 2017. Risk factors influencing the prognosis of the patients were assessed using Kaplan-Meier curves and cox regression models. We compared the results with 55 randomly selected patients with gastroenteropancreatic GEP neuroendocrine tumors, 47 with neuroendocrine carcinomas (NEC), and 58 with poorly differentiated adenocarcinoma.

RESULTS

Among the 46 patients with GEP-MiNEN, thirty-five had gastric tumors, nine had intestinal tumors (four in the small intestine and five in the colon and rectum), and two had pancreatic tumors. The median age of the patients was 66 (41-84) years, and the male-to-female ratio was 2.83. Thirty-three (71.7%) patients had clinical stage III and IV cancers. Distant metastasis occurred in 14 patients, of which 13 had metastasis to the liver. The follow-up period was 11-72 mo, and the median overall survival was 30 mo. Ki-67 index ≥ 50%, high proportion of NEC, lymph node involvement, distant metastasis, and higher clinical stage were independent risk factors affecting the prognosis of patients with GEP-MiNEN. The median overall survival was shorter for patients with NEC than for those with MiNEN (14 mo *vs* 30 mo, *P* = 0.001), but did not significantly differ from those with poorly differentiated adenocarcinoma and MiNEN (30 mo *vs* 18 mo, *P* = 0.453).

CONCLUSION

A poor prognosis is associated with rare, aggressive GEP-MiNEN. Ki-67 index, tumor composition, lymph node involvement, distant metastasis, and clinical stage are important factors for patient prognosis.

**Key Words:** Mixed neuroendocrine non-neuroendocrine neoplasm; Mixed adenoneuroendocrine carcinoma; Prognosis; Gastro-entero-pancreatic tract

Huang YC, Yang NN, Chen HC, Huang YL, Yan WT, Yang RX, Li N, Zhang S, Yang PP, Feng ZZ. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients. *World J Gastroenterol* 2021; In press

**Core Tip:** A poor prognosis is associated with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasms, a rare, aggressive type of tumor. Ki-67 index, tumor composition, lymph node involvement, distant metastasis, and clinical stage are important factors for patient prognosis.

**INTRODUCTION**

Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) comprise a group of extremely rare heterogeneous tumors, accounting for > 5% of all gastrointestinal neuroendocrine tumors[1]. However, their prevalence might be largely underestimated due to diagnostic limitations and insufficient scientific understanding[2]. This type of tumor is characterized by a mixture of neuroendocrine and non-neuroendocrine components, each accounting for > 30% of the tumor. The most common combination is a mixture of adenocarcinomas and neuroendocrine carcinomas, defined as mixed adeno-neuroendocrine carcinoma (MANEC) in the 2010 version of the World Health Organization (WHO) digestive system tumor classification. Although non-neuroendocrine components are usually adenocarcinomas, they can also be squamous cell carcinomas, sarcomas, or other types of tumors[3-5]. The 2019 edition of the WHO digestive system classification categorizes MANEC as MiNEN, which comprises a mixture of other types of tumors and neuroendocrine neoplasms, and thus comprehensively describes the potential biological entities that constitute this tumor[4].

MiNEN have been identified in the stomach, intestines, pancreas, biliary tract, appendix, and cervix. The clinical manifestations, treatment, and prognosis of this type of tumor are not clear due to a dearth of reports[4,6-8]. We retrospectively analyzed the clinicopathological data of 46 patients with gastroenteropancreatic MiNEN (GEP-MiNEN) and identified risk factors that influence prognosis. We also compared prognostic differences between GEP-MiNEN and gastroenteropancreatic neuroendocrine tumors (NET), neuroendocrine carcinomas (NEC), and poorly differentiated adenocarcinoma to improve the understanding of GEP-MiNEN and to guide future clinical treatment.

**MATERIALS AND METHODS**

***Patient selection***

We searched the pathological databases of the First Affiliated Hospital of Bengbu Medical College (Bengbu, China) using the following keywords: Mixed adenoneuroendocrine carcinoma, MANEC, mixed neuroendocrine non-neuroendocrine tumor, and MiNEN between January 2013 and December 2017, and limited the tumor site to the gastrointestinal tract and the pancreas. We retrieved data on 46 patients who matched the diagnostic criteria. Two senior pathologists reviewed and categorized these patients according to the current diagnostic criteria for MiNEN as defined by the WHO (2019). This study was approved by the Ethics Committee of The First Affiliated Hospital of Bengbu Medical College (No. 2020057). All patients provided written informed consent to use their clinical data.

***Inclusion criteria***

The WHO (2019) classifies MiNEN as tumors of the digestive system characterized by presence of neuroendocrine and non-neuroendocrine components, each accounting for > 30% of the tumor[4]. The inclusion criteria were as follows: All patients were treated surgically, including by endoscopy and laparotomy; the postoperative pathology was diagnosed as MiNEN by two senior doctors; the tumor was in the stomach, intestine, or pancreas, and the patient had no history of other malignant tumors; and preoperative radiotherapy or chemotherapy had not been administered.

***Methods***

Tumor tissues were fixed with 10% neutral formaldehyde, embedded in paraffin, sliced into 4 μm-thick sections, and then stained with hematoxylin and eosin. The sections were histologically analyzed using a light microscope. Tumors were clinically staged according to the American Joint Committee on Cancer (8th edition).

Sections were immunohistochemically analyzed using the EnVision method with the following primary monoclonal antibodies for Ki-67 (mouse anti-human antibody, clone MIB-1), cluster of differentiation (CD) 56 (mouse anti-human antibody, clone 56C04), synaptophysin (rabbit anti-human antibody, clone SP11), and chromogranin A (CgA; rabbit anti-human antibody, clone SP12) (all from Maixin Biotechnology Co., Ltd., Fuzhou, China). Ki-67 staining revealed brownish-yellow granules in the nuclei of tumor cells, and ≥ 20%, 21%-50%, and ≥ 51% stained nuclei were regarded as immunohistochemically positive, low expression, and high expression, respectively. The CD56 signal was observed on cell membranes, whereas Syn and CgA signals were located in the cytoplasm. Overall survival (OS) was defined as the time elapsed from the date of surgery to the date of death or the end of follow-up.

***Follow-up***

Follow-up was conducted for 46 patients by either reviewing their information files, making phone calls, or sending out e-mails from the date of diagnosis until December 31, 2019. The OS of the patients who survived or were lost to follow-up was excluded at the date of their last follow-up.

***Statistical analysis***

Data were statistically analyzed using statistic package for social science 25.0 (IBM Corp., Armonk, NY, United States). Categorical and continuous variables were analyzed using chi-square tests and independent-sample *t*-test, respectively. Survival was assessed using univariate Kaplan-Meier analysis and survival curves. Survival rates between groups were compared using log-rank tests, and OS rates were analyzed using multivariate Cox regression models. Values with *P* < 0.05 were considered statistically significant. The statistical methods were reviewed by Lian-guo Fu from Bengbu Medical College.

**RESULTS**

***Clinicopathological information of patients***

The clinicopathological data of 46 patients (males, *n* = 34; male-to-female ratio, 2.83: 1; average age, 65 (41-84) years; median age, 66 years) with GEP-MiNEN were analyzed. Among the forty-six patients, thirty-five patients had gastric tumors, nine had intestinal tumors, and two had pancreatic tumors. The tumor diameter was ≥ 5 and < 5 cm in 29 and 17 patients, respectively. Microscopy revealed a significant proportion of tumors categorized as NEC and as adenocarcinoma in 28 (60.9%) and 18 (39.1%) patients, respectively. Nerve invasion and vascular tumor thrombus were evident in 27 (58.7%) and 26 (56.5%) of the 46 patients, respectively. Furthermore, 34 (74.0%) of the 46 patients had lymph node involvement, and 14 (30.4%) had distant metastasis. Tumors metastasized to the liver in thirteen of these fourteen patients (three tumors were discovered during surgery), and to the ovary in one patient (Table 1).

***Microscopic and immunohistochemical features***

The 46 patients exhibited GEP-MiNEN comprising medium or poorly differentiated adenocarcinoma combined with neuroendocrine carcinoma (Figure 1A). Among them, thirty-three had poorly differentiated adenocarcinoma and four had mucinous adenocarcinomas. In 13 patients with moderately differentiated adenocarcinoma, the neuroendocrine component was NEC G3. The adenocarcinoma in these patients had an irregular papillary, adenoid, sieve, or nested distribution, and cells had round or oval nuclei, and coarse and granular chromatin (Figure 1B). The neuroendocrine carcinomas were nested, with an organoid-like distribution, and comprised small cubic or cylindrical tumor cells with round nuclei, reduced cytoplasm, an increased nucleoplasm ratio, and fine nuclear chromatin (Figure 1C).

The adenocarcinoma components expressed cytokeratin (Figure 1D), and most did not express neuroendocrine cancer markers. The neuroendocrine cancer components expressed CgA, Syn, and CD56. All patients were positive for CgA (Figure 1E), 35 were positive for Syn (76.1%) (Figure 1F), and 32 were positive for CD56 (69.6%). The Ki-67 proliferation index was > 50% (high expression) and < 50% (low expression) in 29 and 17 patients, respectively.

***Follow-up and survival analysis***

Follow-up was conducted for the patients for a median of 39 (11-72) mo. As of December 31, 2019, a total of forty-two cases were subjected to follow-up and four cases were lost to the follow-up process (8.7%). By the end of the follow-up process, 27 patients had succumbed to tumor-related death. The average and median survivals were 28.60 ± 15.14 and 30 mo, respectively (range, 12-43 mo). Univariate analysis using log-rank tests indicated that the age of the patients, tumor size, Ki-67 index, tumor composition (proportion of neuroendocrine and non-neuroendocrine tumor), degree of adenocarcinoma differentiation, lymph node involvement, vascular tumor thrombus, neurological recidivism, distant metastasis, and clinical stage were associated with OS (*P* ​​< 0.05). Table 2 and Figure 2A-J respectively show the results of univariate analysis of survival and survival curves. Patients aged ≥ 65 years with a tumor diameter ≥ 5 cm, a Ki-67 index ≥ 50, high NEC, poorly differentiated adenocarcinoma, lymph node involvement, vascular tumor thrombus, nerve invasion, distant metastasis, and high clinical stage had a reduced OS. Sex (*P* = 0.464) and tumor location (*P* = 0.056) were not significantly associated with OS.

Meaningful indicators in the univariate analysis were included in the Cox regression analysis, and the results showed that Ki-67 index ≥ 50% (*P* = 0.008), lymph node involvement (95%CI: 1.667-25.197, *P* = 0.007), distant metastasis (95%CI: 0.037-0.540, *P* = 0.004), increased proportion of NEC (*P* = 0.039), and clinical stage (*P* = 0.024) were independent risk factors that affected the OS of patients with GEP-MiNEN (Figure 2K and Table 3).

***Comparative analysis of GEP-MiNEN, NET, and NEC***

We selected 55 patients [males, *n* = 24; average age at diagnosis, 49 (11-85) years] with gastrointestinal pancreatic neuroendocrine tumors (GEP-NET) in the intestine (*n* = 39), pancreas (*n* = 9), and stomach (*n* = 7). The average tumor size was 1.7 cm. Lymph nodes were involved in 13 patients, and two had distant metastasis (the small intestine was the primary site of all tumors; one case metastasized to the liver and the other to the pancreas). Eight of the fifty-five patients were lost to follow-up. Tumor location, lymph node involvement, and distant metastasis significantly differed between patients with GEP-NET and MiNEN. By the end of the follow-up period, the median OS was significantly longer in the patients with NET than in the patients with MiNEN (50 mo *vs* 30 mo, *P* < 0.001).

We selected 47 patients [males, *n* = 34; average age at diagnosis, 64 (range, 40-83 years)] with gastrointestinal pancreatic neuroendocrine carcinoma (GEP-NEC) tumors located in the stomach (*n* = 26), intestine (*n* = 15), and pancreas (*n* = 6). The average tumor size was 5.2 cm. Lymph nodes were involved in 33 cases, and 21 patients had distant metastasis. Tumors metastasized to the pancreas (*n* = 1), to both the liver and rectum (*n* = 1), abdominal cavity (*n* = 4), and liver (*n* = 15). Six patients were lost to follow-up. The effects of sex, age, tumor size, tumor location, lymph node involvement, and distant metastasis on OS did not significantly differ between GEP-NEC and MiNEN (*P* > 0.05 for all). The median OS was significantly shorter in the patients with GEP-NEC than in those with MiNEN (14 *vs* 30 mo, *P* = 0.001; Table 4).

***Comparative analysis of GEP-MiNEN and poorly differentiated adenocarcinoma***

We selected 58 patients [average age, 61 (31-81) years; male, *n* = 37] with poorly differentiated gastrointestinal pancreatic adenocarcinoma located in the stomach (*n* = 42), intestines (*n* = 12), and pancreas (*n* = 4). The tumors were < 5 and ≥ 5 cm in 25 and 33 patients, respectively. Lymph node involvement and distant metastasis were found in 47 and 16 patients, respectively. Sex, age, tumor size, tumor location, lymph node involvement, and distant metastasis did not significantly differ between the two groups (*P* > 0.05 for all); median OS did not differ either (30 mo *vs* 18 mo, *P* = 0.453; Table 5).

**DISCUSSION**

In the 2010 WHO classification of digestive diseases, MANEC is defined as “a tumor with the morphologically recognizable glandular epithelial and neuroendocrine phenotype and is defined as cancer because both components are malignant.” A mixture of squamous cell carcinoma and neuroendocrine components has also been identified in some esophageal and anal tumors[4]. At least 30% of malignancies are deemed eligible for classification as MANEC[9]. For instance, a typical adenocarcinoma without the morphological characteristics of a neuroendocrine tumor, in which immunohistochemical staining reveals scattered neuroendocrine markers, should not be diagnosed as "adenocarcinoma with neuroendocrine differentiation". In 2017, the classification of pancreatic neuroendocrine tumors was modified by the WHO and classified together with digestive tumors. The previous term, MANEC, was replaced by MiNEN[10]. The WHO stipulated in 2019 that the term MiNEN is applicable to all digestive tract and neuroendocrine tumors of the digestive system and that these tumors are classified as NET, NEC, and MiNEN. The MiNEN comprise non-neuroendocrine (mostly adenomas or adenocarcinomas, and rarely squamous cell carcinomas) and neuroendocrine components (NETG1, NETG2, NEC), either of which must account for at least 30% of the tumor[11,12]. While MiNEN have been found in most organs, they are usually found in the gastrointestinal tract and pancreas[5,13,14].

The diagnosis of MiNEN is primarily based on tumor cytology and structure, and neuroendocrine components can be confirmed by immunolabeling with synaptophysin, chromogranin A, and CD56[7]. The recent widespread application of immunohistochemistry has shown that MiNEN tumors are not as rare as previously hypothesized, and the morbidity and mortality rates of gastrointestinal MiNEN are constantly increasing at an alarming pace[15]. However, knowledge of MiNEN remains limited. The two cellular components of MiNEN are difficult to distinguish, especially when both are poorly differentiated, and they are often misdiagnosed as adenocarcinomas or grade 3 neuroendocrine tumors[16]. We identified MiNEN as a combination of moderately or poorly differentiated adenocarcinoma and NEC. Therefore, in addition to NET, our control group comprised patients with NEC and poorly differentiated adenocarcinoma.

Most MiNEN cases develop slowly and manifest as nonspecific clinical symptoms like those of traditional adenocarcinoma. The disease, for many patients, is usually in its advanced stages by the time when a physician is consulted, and most demonstrate lymph node and distant metastasis, indicating that most conventional adenocarcinoma cases with MiNEN are characterized by aggressive behavior and a poor prognosis[7,16]. The GEP-MiNEN tumors analyzed herein were most prevalent in the stomach of the 46 patients, followed by the intestine and pancreas. We found that 58.7%, 56.5%, 74.0%, and 30.4% of the patients had nerve invasion, vascular tumor thrombus, lymph node involvement, and distant metastasis, respectively. The most common site of distant metastasis was the liver [13 (28.3%) of 46]. Lymph node involvement (*P* = 0.007) and distant metastasis (*P* = 0.004) were independent risk factors for the OS of patients. These results suggest that MiNEN cases have significant invasive potential.

Nie *et al*[17] suggested that the degree of differentiation of the adenocarcinoma and the neuroendocrine cancer cells of gastric MANEC affect prognosis. A lower degree of cancer cell differentiation was associated with a worse prognosis. The prognosis of patients with gastrointestinal MANEC largely depends on the stage and type of neuroendocrine components of the tumor, suggesting that NEC components comprise a key prognostic indicator[7,14,18-20]. Park *et al*[21] have suggested that gastric cancer with neuroendocrine differentiation indicates a poor prognosis, and the degree of such differentiation can serve as an independent prognostic indicator.

The neuroendocrine components of the 46 analyzed GEP-MiNEN were NEC G3, and the adenocarcinomas were either moderately differentiated or poorly differentiated. The median OS was significantly shorter for patients with poorly differentiated adenocarcinoma, compared to that observed in those with moderately differentiated adenocarcinoma (20 mo *vs* 40 mo, *P* = 0.001). Furthermore, the median OS was significantly shorter in patients with major NEC compared to that in patients with major adenocarcinoma (20 mo *vs* 43 mo, *P* = 0.002). Multivariate analysis selected major NEC as an independent risk factor for OS (95%CI: 1.065-11.286, *P* = 0.039). This further shows that the degree of adenocarcinoma differentiation and the proportion of NEC severely impact the survival and prognosis of patients, which is consistent with the findings of previous studies[2,17,18,22,23].

Xie *et al*[19] examined 80 patients with gastric MANEC and associated a Ki-67 index ≥ 60% with poor survival and higher recurrence rates. Milione *et al*[23] have reported that the Ki-67 index of the NEC component is the most powerful prognostic indicator, and that the risk of death is 8 -fold higher in patients with Ki-67 ≥ 55% than in those with Ki-67 < 55%. The median OS of our patients was significantly shorter for patients with a Ki-67 index ≥ 50% than for those with a Ki- 67 index < 50% (25 mo *vs* 43 mo, *P* = 0.002). In line with previous studies, we also identified the Ki-67 index as an independent prognostic indicator of OS (95%CI: 1.466-12.459, *P* = 0.008).

Among the 46 patients examined herein, 33 (71.7%) had clinical stages III and IV GEP-MiNEN at the time of diagnosis. By the end of the follow-up, 22 of these 33 patients succumbed (within an average of 20.13 mo). The median OS was significantly shorter for patients with stages III and IV, compared to that in patients with stage I + II tumors (20 mo *vs* 40 mo, *P* < 0.001). Multivariate analysis showed that clinical stage was an independent risk factor for the OS of the patients (95%CI: 0.077-0.837, *P* = 0.024), which was consistent with the findings of the study by Song *et al*[24]. Our findings were in line with those of a previous study in which a prognostic model based on tumor node metastasis staging combined with tumor composition ratio and Ki-67 index achieved a similar discriminative ability[19].

Brathwaite *et al*[16] found that the prognosis was worse for MANEC than conventional adenocarcinoma and low-grade neuroendocrine tumors. Others[22] have suggested that the prognosis of gastric MANEC is worse than that of gastric adenocarcinoma. However, whether the prognosis is better for patients with gastric MANEC than NEC patients is not clear. One study found no significant differences in survival between patients with gastric and colorectal MANEC and NEC[25]. Watanabe *et al*[26] found that disease-free survival and OS rates were significantly lower among patients with MANEC than patients with adenocarcinoma. The prognosis of patients, especially those with stage III MANEC, is as poor as that of NEC patients compared with colorectal adenocarcinoma. La Rosa *et al*[27] suggested that MANEC tumors containing well-differentiated NET and adenocarcinoma components should be regarded as adenocarcinomas, while MANEC tumors containing poorly differentiated NEC components should be regarded as NEC.

We found that 34 (74.0%) of the 46 patients with MiNEN had lymph node involvement, which was slightly more than the 33 (70.2%) of the 47 patients with NEC. However, distant metastasis was more prevalent in patients with NEC than in those with MiNEN [21 (44.7%) of 47 *vs* 14 (30.4%) of 46], which was consistent with previous findings[6,28]. Furthermore, the metastatic behavior of the two types of tumors might differ; MiNEN usually involve regional lymph nodes, while NEC frequently exhibit distant metastasis, suggesting that NEC are more aggressive. We found that the median OS was significantly longer for patients with MiNEN than those with NEC (30 mo *vs* 14 mo, *P* = 0.001).

Few reports have described the prognosis of patients with MiNEN and poorly differentiated adenocarcinoma. Among forty-two of the forty-six patients with GEP-MiNEN who had complete follow-up data, fourteen had distant, thirteen had liver, and one had ovarian metastases. Among the 50 out of the 58 patients with poorly differentiated adenocarcinoma who had complete follow-up data, 16 developed distant metastases to the liver (*n* = 10), abdominal cavity (*n* = 4), and ovaries (*n* = 2), where a Klugenberg tumor formed. Sex, age, tumor size, tumor location, Ki-67 index, lymph node involvement, distant metastasis, and clinical stage did not significantly differ between patients with MiNEN and those with poorly differentiated adenocarcinoma (*P* > 0.05 for all). Furthermore, median OS did not significantly differ between these patients (30 mo *vs* 18 mo, *P* = 0.453).

Although the histological origin and molecular mechanism of MiNEN remain controversial, the findings of the existing molecular and genetic studies on MiNEN of the digestive system have shown that neuroendocrine and non-neuroendocrine components share a common monoclonal origin[29-32]. The origin of MiNEN is associated with mutations in MiNEN-related genes, including *TP53*, *BRAF*, and *KRAS*[2,16,25], of which the *TP53* mutation is the most common[29]. Milione *et al*[23] showed a higher frequency of chromosomal and genetic abnormalities in neuroendocrine, compared to that in non-neuroendocrine components, indicating that non-neuroendocrine progression to a neuroendocrine cellular phenotype was more frequent than previously thought. Microsatellite instability might be a driving factor for the development of gastrointestinal neuroendocrine tumors[16]. Conventional colorectal adenocarcinomas and MANEC might have a common genetic profile[25], and might respond to chemotherapy for colorectal adenocarcinoma, revealing a genetic connection between most colorectal MANEC and NET and the adenocarcinoma family.

In the absence of contraindications, the main treatment following a diagnosis of GEP-MiNEN is radical surgery. Chemotherapy is the treatment of choice for poorly differentiated, or rapidly progressing advanced tumors. Cisplatin/5-FU combined with etoposide is the most common chemotherapeutic regimen applied to treat MiNEN and is similar to those used to treat adenocarcinomas[12,31,33]. Neoadjuvant chemotherapy significantly improves the OS of patients with locally advanced NEC and MANEC in the stomach with an acceptable level of toxicity[34]. Surgical removal of each metastasis combined with systemic chemotherapy can significantly improve the prognosis of patients with colorectal MiNEN tumors that have already metastasized to distant locations[35]. An optimal combination of systemic chemotherapy and somatostatin analogs such as octreotide and lanreotide can prolong the progression-free survival of patients with metastatic neuroendocrine tumors[12].

**CONCLUSION**

Overall, GEP-MiNEN are rare and heterogeneous tumors with a highly variable prognosis for which there are no clear treatment guidelines. Although we found a worse prognosis for patients with MiNEN than for those with NEC, it did not significantly differ from that of patients with poorly differentiated adenocarcinoma. Thus, patients with GEP-MiNEN and those with adenocarcinoma should be similarly treated. Furthermore, the treatment of any suspected or diagnosed GEP-MiNEN patient should be discussed at a multidisciplinary expert meeting to determine optimal personalized treatment for individual patients. The number of patients in the present retrospective study was limited by the rarity of GEP-MiNEN, and they were sourced from a single institution. Therefore, further multicenter, larger-cohort studies are warranted to clarify the clinicopathological features and biological behavior of GEP-MiNEN.

**ARTICLE HIGHLIGHTS**

***Research background***

Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) are a rare tumor type. However, their prevalence might be largely underestimated due to diagnostic limitations and insufficient scientific understanding. The clinical manifestations, treatment, and prognosis of this type of tumor are still poorly understood. Our research on the risk factors, clinical manifestations, and prognosis related to this rare tumor type is of great significance for optimizing clinical treatment.

***Research motivation***

MiNEN associated risk factors, clinical manifestations, and prognosis must be explored to improve our understanding of this rare tumor type and optimize clinical treatment.

***Research objectives***

We have identified the risk factors that influence the prognosis of patients with gastroenteropancreatic MiNEN (GEP-MiNEN). We also compared prognostic differences between GEP-MiNEN and gastroenteropancreatic neuroendocrine tumors, neuroendocrine carcinomas (NEC), and poorly differentiated adenocarcinoma to improve the understanding of GEP-MiNEN and to guide future clinical treatment.

***Research methods***

This is a single-center, retrospective study. We retrospectively analyzed the clinical data of patients who were diagnosed with GEP-MiNEN. Risk factors influencing patient prognosis were assessed using Kaplan-Meier curves and Cox regression models. We compared the results with randomly selected patients with gastroenteropancreatic neuroendocrine tumors, NEC, and poorly differentiated adenocarcinomas.

***Research results***

Most GEP-MiNEN in our study were gastric tumors, a few were intestinal tumors, and a minority, pancreatic tumors. The median overall survival was 30 mo. Ki- 67 index ≥ 50%, high proportion of NEC, lymph node involvement, distant metastasis, and higher clinical stage were independent risk factors affecting the prognosis of patients with GEP-MiNEN. The median overall survival was shorter for patients with NEC than for those with MiNEN but did not significantly differ from those with poorly differentiated adenocarcinoma and MiNEN. Thus, patients with GEP-MiNEN and those with adenocarcinoma should be similarly treated. Furthermore, the treatment of any suspected or diagnosed GEP-MiNEN patient should be discussed at a multidisciplinary expert meeting to determine optimal personalized treatment. However, the number of patients in the present retrospective study was limited by the rarity of GEP-MiNEN, and they were sourced from a single institution. Therefore, further multicenter, larger-cohort studies are warranted to clarify the clinicopathological features and biological behavior of GEP-MiNEN.

***Research conclusions***

A poor prognosis is associated with GEP-MiNEN. Ki-67 index, tumor composition, lymph node involvement, distant metastasis, and clinical stage are important factors for patient prognosis.

***Research perspectives***

In view of the limited number of patients and the short-term follow-up of our study, a larger prospective study with long-term follow-up is needed to confirm our results.

**ACKNOWLEDGEMENTS**

We would like to thank Dr. Lian-Guo Fu for significant contributions to data analysis.

**REFERENCES**

1 **de Mestier L**, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P. Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. *Neuroendocrinology* 2017; **105**: 412-425 [PMID: 28803232 DOI: 10.1159/000475527]

2 **Frizziero M**, Chakrabarty B, Nagy B, Lamarca A, Hubner RA, Valle JW, McNamara MG. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. *J Clin Med* 2020; **9** [PMID: 31963850 DOI: 10.3390/jcm9010273]

3 **Merola E,** Zandee WT, de Mestier L, Klumpen HJ, Makulik K, Geboes K, van Velthuysen ML, Couvelard A, Cros J, van Eeden S, Hoorens A, Stephenson T, Zajęcki W, de Herder W, Munir A. Histopathological Revision for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in Expert Centers: Does it Make the Difference? *Neuroendocrinology* 2020 [DOI: 10.1159/000507082]

4 **Assarzadegan N**, Montgomery E. What is New in 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: Review of Selected Updates on Neuroendocrine Neoplasms, Appendiceal Tumors, and Molecular Testing. *Arch Pathol Lab Med* 2020 [PMID: 32233993 DOI: 10.5858/arpa.2019-0665-RA]

5 **La Rosa S**, Sessa F, Uccella S. Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms. *Endocr Pathol* 2016; **27**: 284-311 [PMID: 27169712 DOI: 10.1007/s12022-016-9432-9]

6 **Oneda E**, Liserre B, Bianchi D, Rota L, Savelli G, Zorzi F, Zaniboni A. Diagnosis of Mixed Adenoneuroendocrine Carcinoma (MANEC) after Neoadjuvant Chemotherapy for Pancreatic and Gastric Adenocarcinoma: Two Case Reports and a Review of the Literature. *Case Rep Oncol* 2019; **12**: 434-442 [PMID: 31275134 DOI: 10.1159/000501200]

7 **Pham QD**, Mori I, Osamura RY. A Case Report: Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Aggressive Neuroendocrine Component. *Case Rep Pathol* 2017; **2017**: 9871687 [PMID: 28626594 DOI: 10.1155/2017/9871687]

8 **Qiu S**, Pellino G, Warren OJ, Mills S, Goldin R, Kontovounisios C, Tekkis PP. Mixed adenoneuroendocrine carcinoma of the colon and rectum. *Acta Chir Belg* 2018; **118**: 273-277 [PMID: 29911510 DOI: 10.1080/00015458.2018.1482697]

9 **Bosman FT.** International Agency for Research on Cancer: WHO Classification of Tumours of the Digestive System, 4th ed. Lyon. IARC, 2010

10 **Inzani F**, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. *Endocrinol Metab Clin North Am* 2018; **47**: 463-470 [PMID: 30098710 DOI: 10.1016/j.ecl.2018.04.008]

11 **Nagtegaal ID**, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. *Histopathology* 2020; **76**: 182-188 [PMID: 31433515 DOI: 10.1111/his.13975]

12 **Skalický A**, Vištejnová L, Dubová M, Malkus T, Skalický T, Troup O. Mixed neuroendocrine-non-neuroendocrine carcinoma of gallbladder: case report. *World J Surg Oncol* 2019; **17**: 55 [PMID: 30902091 DOI: 10.1186/s12957-019-1598-4]

13 **Di Palma S**, Mufaddal M, Iyer V, Sciarra A, La Rosa S. Does Mixed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN) of the Parathyroid Gland Exist? First Description of a Possible Case. *Head Neck Pathol* 2020 [PMID: 32506375 DOI: 10.1007/s12105-020-01178-4]

14 **Frizziero M**, Wang X, Chakrabarty B, Childs A, Luong TV, Walter T, Khan MS, Morgan M, Christian A, Elshafie M, Shah T, Minicozzi A, Mansoor W, Meyer T, Lamarca A, Hubner RA, Valle JW, McNamara MG. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. *World J Gastroenterol* 2019; **25**: 5991-6005 [PMID: 31660035 DOI: 10.3748/wjg.v25.i39.5991]

15 **Wang J**, He A, Feng Q, Hou P, Wu J, Huang Z, Xiao Z, Sun C, Liao W, Wu L. Gastrointestinal mixed adenoneuroendocrine carcinoma: a population level analysis of epidemiological trends. *J Transl Med* 2020; **18**: 128 [PMID: 32169074 DOI: 10.1186/s12967-020-02293-0]

16 **Brathwaite SA**, Smith SM, Wai L, Frankel W, Hays J, Yearsley MM, Abdel-Misih S. Mixed adenoneuroendocrine carcinoma: A review of pathologic characteristics. *Hum Pathol* 2018; **73**: 184-191 [PMID: 29288693 DOI: 10.1016/j.humpath.2017.12.009]

17 **Nie L**, Li M, He X, Feng A, Wu H, Fan X. Gastric mixed adenoneuroendocrine carcinoma: correlation of histologic characteristics with prognosis. *Ann Diagn Pathol* 2016; **25**: 48-53 [PMID: 27806846 DOI: 10.1016/j.anndiagpath.2016.09.004]

18 **Harada K**, Sato Y, Ikeda H, Maylee H, Igarashi S, Okamura A, Masuda S, Nakanuma Y. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. *Virchows Arch* 2012; **460**: 281-289 [PMID: 22358181 DOI: 10.1007/s00428-012-1212-4]

19 **Xie JW**, Lu J, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Li P, Huang CM. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients. *BMC Cancer* 2018; **18**: 1021 [PMID: 30348122 DOI: 10.1186/s12885-018-4943-z]

20 **Zheng SL**, Yip VS, Pedica F, Prachalias A, Quaglia A. Intrahepatic bile duct mixed adenoneuroendocrine carcinoma: a case report and review of the literature. *Diagn Pathol* 2015; **10**: 204 [PMID: 26589730 DOI: 10.1186/s13000-015-0439-1]

21 **Park JY**, Ryu MH, Park YS, Park HJ, Ryoo BY, Kim MG, Yook JH, Kim BS, Kang YK. Prognostic significance of neuroendocrine components in gastric carcinomas. *Eur J Cancer* 2014; **50**: 2802-2809 [PMID: 25201164 DOI: 10.1016/j.ejca.2014.08.004]

22 **Sun L**, Zhang J, Wang C, Zhao S, Shao B, Guo Y, Liu Y, Sun Y. Chromosomal and molecular pathway alterations in the neuroendocrine carcinoma and adenocarcinoma components of gastric mixed neuroendocrine-nonneuroendocrine neoplasm. *Mod Pathol* 2020; **33**: 2602-2613 [PMID: 32461621 DOI: 10.1038/s41379-020-0579-z]

23 **Milione M**, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P, Vanoli A, Tagliabue G, Pisa E, Messerini L, Centonze G, Inzani F, Scarpa A, Papotti M, Volante M, Sessa F, Fazio N, Pruneri G, Rindi G, Solcia E, La Rosa S, Capella C. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. *Endocr Relat Cancer* 2018; **25**: 583-593 [PMID: 29592868 DOI: 10.1530/ERC-17-0557]

24 **Song LJ**, Yuan L. Comparative analysis of colorectal mixed adenoneuroendocrine carcinoma and adenocarcinoma with neuroendocrine differentiation: a population-based study. *Int J Clin Exp Pathol* 2019; **12**: 922-932 [PMID: 31933902]

25 **Jesinghaus M**, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M, Penzel R, Endris V, Arsenic R, Hermann G, Stenzinger A, Weichert W, Pfarr N, Klöppel G. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. *Mod Pathol* 2017; **30**: 610-619 [PMID: 28059096 DOI: 10.1038/modpathol.2016.220]

26 **Watanabe J**, Suwa Y, Ota M, Ishibe A, Masui H, Nagahori K, Tsuura Y, Endo I. Clinicopathological and Prognostic Evaluations of Mixed Adenoneuroendocrine Carcinoma of the Colon and Rectum: A Case-Matched Study. *Dis Colon Rectum* 2016; **59**: 1160-1167 [PMID: 27824701 DOI: 10.1097/DCR.0000000000000702]

27 **La Rosa S**, Marando A, Sessa F, Capella C. Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update. *Cancers (Basel)* 2012; **4**: 11-30 [PMID: 24213223 DOI: 10.3390/cancers4010011]

28 **Zhang P**, Wang W, Lu M, Zeng C, Chen J, Li E, Tan H, Wang W, Yu X, Tang Q, Zhao J, Shen L, Li J. Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. *Cancer Med* 2018; **7**: 4361-4370 [PMID: 30062861 DOI: 10.1002/cam4.1702]

29 **Scardoni M**, Vittoria E, Volante M, Rusev B, Bersani S, Mafficini A, Gottardi M, Giandomenico V, Malleo G, Butturini G, Cingarlini S, Fassan M, Scarpa A. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components. *Neuroendocrinology* 2014; **100**: 310-316 [PMID: 25342539 DOI: 10.1159/000369071]

30 **Paniz Mondolfi AE**, Slova D, Fan W, Attiyeh FF, Afthinos J, Reidy J, Pang Y, Theise ND. Mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: a possible stem cell tumor? *Pathol Int* 2011; **61**: 608-614 [PMID: 21951672 DOI: 10.1111/j.1440-1827.2011.02709.x]

31 **Gurzu S**, Fetyko A, Bara T, Banias L, Butiurca VO, Bara T Jr, Tudorache V, Jung I. Gastrointestinal mixed adenoneuroendocrine carcinoma (MANEC): An immunohistochemistry study of 13 microsatellite stable cases. *Pathol Res Pract* 2019; **215**: 152697 [PMID: 31704155 DOI: 10.1016/j.prp.2019.152697]

32 **Nassereddine H**, Poté N, Théou-Anton N, Lamoureux G, Fléjou JF, Couvelard A. A gastric MANEC with an adenocarcinoma of fundic-gland type as exocrine component. *Virchows Arch* 2017; **471**: 673-678 [PMID: 28653202 DOI: 10.1007/s00428-017-2178-z]

33 **Zhang M**, Zhao P, Shi X, Zhao A, Zhang L, Zhou L. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. *BMC Endocr Disord* 2017; **17**: 39 [PMID: 28705205 DOI: 10.1186/s12902-017-0190-6]

34 **Ma F**, Wang B, Xue L, Kang W, Li Y, Li W, Liu H, Ma S, Tian Y. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. *J Cancer Res Clin Oncol* 2020; **146**: 2135-2142 [PMID: 32306127 DOI: 10.1007/s00432-020-03214-w]

35 **Kanazawa Y**, Kikuchi M, Imai Y, Katakami N, Kaihara S, Shinohara S. Successful Treatment of a Mixed Neuroendocrine-Nonneuroendocrine Neoplasm of the Colon with Metastases to the Thyroid Gland and Liver. *Case Rep Otolaryngol* 2020; **2020**: 5927610 [PMID: 32099708 DOI: 10.1155/2020/5927610]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Bengbu Medical College.

**Informed consent statement:** All patients provided written informed consent.

**Conflict-of-interest statement:** We have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 15, 2020

**First decision:** December 17, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Tonelli F **S-Editor:** Zhang L **L-Editor:** Wang TQ **P-Editor:**

**Figure legends**



**Figure 1 Histopathological and immunohistochemical findings of gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasms.** A: Neuroendocrine carcinoma (left) and adenocarcinoma (right) (Hematoxylin-eosin staining, scale bar 200 µm); B: Adenocarcinoma component (Hematoxylin-eosin staining, scale bar 200 μm); C: Neuroendocrine component (Hematoxylin-eosin staining, scale bar 100 μm); D: Cytokeratin-positive adenocarcinoma (EnVision, scale bar 100 μm); E: CgA-positive neuroendocrine (EnVision, scale bar 100 μm); F: Syn-positive neuroendocrine (EnVision, scale bar 100 μm).

**Figure 2 Kaplan-Meier curves of overall survival among 46 patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasms.** Overall survival grouped by A: Age (*p* = 0.028); B: Tumor size (*P* = 0.024); C: Ki-67 index (*P* = 0.002); D: Proportions of NEC and adenocarcinoma (*P* = 0.002); E: Adenocarcinoma differentiation (*P* = 0.001); F: Lymph node metastasis (*P* = 0.003); G: Vascular tumor thrombus (*P* < 0.001); H: Nerve invasion (*P* = 0.001); I: Distant metastasis (*P* < 0.001); and J: Clinical stage (*P* < 0.001); K: Overall survival of 46 patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasms.

**Table 1 Patients’ characteristics**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Frequency (*n*)** | **Ratio (%)** |
| Gender |  |  |
| Male | 34 | 73.9 |
| Female | 12 | 26.1 |
| Age (yr) | 66 (41-84) |  |
| < 65 | 20 | 43.5 |
| ≥ 65 | 26 | 56.5 |
| Location |  |  |
| Stomach | 35 | 76.1 |
| Intestine | 9 | 19.6 |
| Pancreas | 2 | 4.3 |
| Size (cm) | 5.4 (0.5-18) |  |
| < 5 cm | 25 | 54.3 |
| ≥ 5 cm | 21 | 45.7 |
| Ki- 67 index |  |  |
| < 50% | 17 | 37.0 |
| ≥ 50% | 29 | 63.0 |
| Proportions of two components |  |  |
| NEC higher | 28 | 60.9 |
| AC higher | 18 | 39.1 |
| Histological grade of adenocarcinoma |  |  |
| Moderately differentiated | 13 | 28.3 |
| Poorly differentiated | 33 | 71.7 |
| Neuroendocrine component |  |  |
| NET | 0 | 0 |
| NEC | 46 | 100 |
| Lymph node metastasis |  |  |
| Presence | 34 | 73.9 |
| Absence | 12 | 26.1 |
| Vascular tumor thrombus |  |  |
| Presence | 26 | 56.5 |
| Absence  Neurological recidivism | 20 | 43.5 |
| Presence | 27 | 58.7 |
| Absence | 19 | 41.3 |
| Distant metastasis |  |  |
| Presence | 14 | 30.4 |
| Absence | 32 | 69.6 |
| Clinical TNM stage |  |  |
| Ⅰ+Ⅱ | 13 | 28.3 |
| Ⅲ | 23 | 50.0 |
| Ⅳ | 10 | 21.7 |

NET: Neuroendocrine tumors; NEC: Neuroendocrine carcinomas.

**Table 2 Univariate analysis of overall survival**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | ***n*** | **Log-rank** | ***P* value** |
| Gender |  | 0.537 | 0.464 |
| Male | 31 |  |  |
| Female | 11 |  |  |
| Age (yr) |  | 4.815 | 0.028 |
| < 65 | 17 |  |  |
| ≥ 65 | 25 |  |  |
| Location |  | 5.747 | 0.056 |
| Stomach; Intestine | 32; 8 |  |  |
| Pancreas | 2 |  |  |
| Size (cm) |  | 5.106 | 0.024 |
| < 5 cm | 22 |  |  |
| ≥ 5 cm | 20 |  |  |
| Ki-67 index |  | 9.349 | 0.002 |
| < 50% | 17 |  |  |
| ≥ 50% | 25 |  |  |
| Proportion of the two components |  | 9.421 | 0.002 |
| NEC higher | 26 |  |  |
| AC higher | 16 |  |  |
| Histological grade of adenocarcinoma |  | 11.303 | 0.001 |
| Moderately differentiated | 13 |  |  |
| Poorly differentiated | 29 |  |  |
| Lymph node metastasis |  | 8.800 | 0.003 |
| Presence | 32 |  |  |
| Absence | 10 |  |  |
| Vascular tumor thrombus |  | 12.250 | < 0.001 |
| Presence | 25 |  |  |
| Absence | 17 |  |  |
| Neurological recidivism |  | 11.056 | 0.001 |
| Presence | 26 |  |  |
| Absence | 16 |  |  |
| Distant metastasis |  | 44.917 | < 0.001 |
| Presence | 10 |  |  |
| Absence | 32 |  |  |
| Clinical TNM stage |  | 48.942 | < 0.001 |
| Ⅰ+Ⅱ | 13 |  |  |
| Ⅲ | 19 |  |  |
| Ⅳ | 10 |  |  |

NEC: Neuroendocrine carcinomas; TNM: Tumor node metastasis.

**Table 3 Multivariate Cox regression analysis results of overall survival**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **B** | **SE** | **Wald** ***χ*2** | ***P* value** | **HR** | **95%CI** |
| Ki-67 index | 1.452 | 0.546 | 7.078 | 0.008 | 4.273 | 1.466-12.459 |
| Lymph node metastasis | 1.869 | 0.693 | 7.277 | 0.007 | 6.481 | 1.667-25.197 |
| Distant metastasis | -1.962 | 0.686 | 8.171 | 0.004 | 0.141 | 0.037-0.540 |
| NEC/AC proportion | 1.243 | 0.602 | 4.262 | 0.039 | 3.467 | 1.065-11.286 |
| Clinical stage | -1.374 | 0.610 | 5.070 | 0.024 | 0.253 | 0.077-0.837 |

NEC: Neuroendocrine carcinomas; CI: Confidence interval; HR: Hazard ratio.

**Table 4 Comparative of** **mixed neuroendocrine-non-neuroendocrine neoplasms, neuroendocrine tumors, and neuroendocrine carcinomas**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **NET** **(*n* = 55)** | **NEC** **(*n* = 47)** | **MiNEN** **(*n* = 46)** | ***P* value** | |
|  |  |  |  | NET *vs* MiNEN | NEC *vs* MiNEN |
| Male/female | 24/31 | 34/13 | 34/12 | 0.004 | 0.864 |
| Age [yr, mean (range)] | 49 (11-85) | 64 (40-83) | 65 (41-84) | < 0.001 | 0.857 |
| Location |  |  |  | < 0.001 | 0.162 |
| Stomach | 7 | 26 | 35 |  |  |
| Intestine | 39 | 15 | 9 |  |  |
| Pancreas | 9 | 6 | 2 |  |  |
| Size [cm, mean (range)] | 1.7 (0.2-11) | 5.2 (1.5-16.0) | 5.4 (0.5-18) | < 0.001 | 0.742 |
| Ki-67 index |  |  |  | < 0.001 | 0.051 |
| < 2% | 15 | 2 | 0 |  |  |
| 2%-20% | 39 | 5 | 1 |  |  |
| > 20% | 1 | 40 | 45 |  |  |
| Lymph node |  |  |  | < 0.001 | 0.691 |
| metastasis |  |  |  |  |  |
| Presence | 13 | 33 | 34 |  |  |
| Absence | 42 | 14 | 12 |  |  |
| Distant metastasis |  |  |  | < 0.001 | 0.156 |
| Presence | 2 | 21 | 14 |  |  |
| Absence | 53 | 26 | 32 |  |  |
| Survival time |  |  |  | < 0.001 | 0.001 |
| (mo) |  |  |  |  |  |
| Median | 50 | 14 | 30 |  |  |
| Mean | 49.3 | 34 | 28.6 |  |  |
| Follow-up |  |  |  | < 0.001 | 0.054 |
| Dead | 3 | 34 | 27 |  |  |
| Alive | 44 | 7 | 15 |  |  |

MiNEN: Mixed neuroendocrine-non-neuroendocrine neoplasms; NET: Neuroendocrine tumors; NEC: Neuroendocrine carcinomas.

**Table 5 Comparison between patients with** **mixed neuroendocrine-non-neuroendocrine neoplasms and those with poorly differentiated adenocarcinoma**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Poorly differentiated adenocarcinoma (*n* = 58)** | **MiNEN (*n* = 46)** | ***P* value** |
| Male/female | 37/21 | 34/12 | 0.271 |
| Mean age, years, (range) | 61 (31-81) | 65 (41-84) | 0.055 |
| Location |  |  | 0.836 |
| Stomach | 42 | 35 |  |
| Intestine | 12 | 9 |  |
| Pancreas | 4 | 2 |  |
| Size (cm) |  |  | 0.254 |
| < 5 | 25 | 25 |  |
| ≥ 5 | 33 | 21 |  |
| Ki- 67 index |  |  | 0.104 |
| < 50% | 13 | 17 |  |
| ≥ 50% | 45 | 29 |  |
| Lymph node metastasis |  |  | 0.385 |
| Presence | 47 | 34 |  |
| Absence | 11 | 12 |  |
| Distant metastasis |  |  | 0.750 |
| Presence | 16 | 14 |  |
| Absence | 42 | 32 |  |
| Clinical TNM stage |  |  | 0.402 |
| Ⅰ+Ⅱ | 10 | 13 |  |
| Ⅲ | 34 | 23 |  |
| Ⅳ | 14 | 10 |  |
| Survival time (mo) |  |  | 0.453 |
| Median | 18 | 30 |  |
| Mean | 24.3 | 28.6 |  |
| Follow-up |  |  | 0.863 |
| Dead | 33 | 27 |  |
| Alive | 17 | 15 |  |

MiNEN: Mixed neuroendocrine-non-neuroendocrine neoplasms; TNM: Tumor node metastasis.